The Latest Cardiac and Vascular News
PARIS, May 17, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) announced today that new data from the Benchmark Registry in Europe demonstrated the safety and effectiveness of this streamlined treatment pathway for patients receiving transcatheter aortic valve replacement (TAVR) with balloon-expandable valves. The data were presented in a late-breaking clinical data session at EuroPCR 2023. […]
IRVINE, Calif., April 26, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2023. Highlights and Outlook Q1 sales grew 9 percent to $1.46 billion; constant currency1 sales grew 13 percent Q1 TAVR sales grew 8 percent; constant currency sales grew 11 percent Q1 EPS of $0.56; adjusted1 EPS of $0.62 […]
Hoag is one of the first three sites in the nation enrolling patients in a post-market study Hoag cardiac surgeons are among an elite class of specialists experienced with this latest generation valve option Study expected to grow to include centers around the world NEWPORT BEACH, Calif., April 17, 2023 /PRNewswire/ — […]
NEW ORLEANS, March 6, 2023 — Edwards Lifesciences (NYSE: EW) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) sufferers, along with data examining 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using real-world Medicare data. Together these studies, presented at the American College […]
IRVINE, Calif., Jan. 31, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook Q4 sales grew 1 percent to $1.35 billion; constant currency1 sales grew 7 percent Q4 TAVR sales were flat; constant currency sales grew 5 percent Q4 EPS of $0.65; adjusted1 EPS increased 25 […]
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards’ chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company’s Annual Meeting […]
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance1 today during its annual investor conference. Highlights of today’s conference include: Global market opportunity across 4 product groups projected to double to […]
LONDON, Nov. 27, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes. The data were presented during the late-breaking trials session at PCR London […]
IRVINE, Calif., Nov. 1, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement (“ASR”) to repurchase $750 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $1.7 billion of shares in 2022. Under the terms of this ASR, Edwards will receive an initial delivery […]
IRVINE, Calif., Oct. 27, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights and Outlook Q3 sales of $1.32 billion grew 1 percent; constant currency1 sales grew 7 percent Q3 TAVR sales grew 1 percent; constant currency sales grew 6 percent Q3 EPS of $0.55; adjusted1 EPS […]
